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Abstract 
Rationale Prepulse inhibition (PPI) of the acoustic startle response, a measure of sensorimotor 
gating, can be enhanced by nicotine. Moreover, the TT-genotype of the nicotinic 
acetylcholine receptor (nAChR) α3-subunit (CHRNA3) rs1051730 polymorphism has 
previously been associated with diminished PPI and nicotine dependence. Objectives We 
tested whether this CHRNA3 polymorphism also modulates the nicotine-induced 
enhancement of PPI. Methods We assessed the effect of nicotine on PPI, startle reactivity, and 
habituation in 52 healthy non-smoking volunteers genotyped for CHRNA3 rs1051730 in a 
double-blind, placebo-controlled, counterbalanced, within-subjects design. Additionally, 
cotinine plasma levels were measured. Results Nicotine significantly enhanced PPI in TT-
homozygotes only and tended to worsen PPI in TC- and CC-carriers. Additionally, nicotine 
significantly reduced startle habituation. Conclusions The present findings imply that the 
effect of nicotine on sensorimotor gating is modulated by nAChR α3-subunits. Thus, genetic 
variation in nicotinic receptor genes might be an important connecting link between early 
attentional processes and smoking behavior. 
 
Keywords 
Prepulse inhibition, sensorimotor gating, CHRNA3, nicotine, nicotinic acetylcholine receptor, 
rs1051730 
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Introduction 
In humans, prepulse inhibition (PPI) is commonly measured as PPI of the acoustic 
startle reflex: a relatively weak and non-startling noise (the prepulse) is presented 30-500 ms 
before a strong startle-eliciting sound (the pulse) resulting in a reduction of the eye-blink 
startle reflex (Graham 1975). More specifically, PPI is thought to reflect an automatic 
filtering process in which the processing of the prepulse is protected from disruption which 
leads to attenuated processing of the pulse (Baschnagel and Hawk 2008; Graham et al. 1975). 
PPI is commonly viewed as an operational measure of a process called “sensorimotor gating,” 
by which excess or trivial stimuli are screened or “gated out” of awareness so that an 
individual can focus attention on the most salient aspects of the stimulus-laden environment 
(Braff et al. 2001).  
Nicotine, an agonist of nicotinic acetylcholine receptors (nAChR), consistently 
enhances PPI in humans (Baschnagel and Hawk 2008; Della Casa et al. 1998; Duncan et al. 
2001; Kumari et al. 1996; Kumari et al. 1997) and animals (Acri et al. 1995; Acri et al. 1994; 
Curzon et al. 1994; Faraday et al. 1999; Schreiber et al. 2002; Spielewoy and Markou 2004). 
The exact mechanism by which nicotine enhances PPI is not yet understood but one way 
nicotine may improve PPI is by enhancing the diminishment of the processing of the pulse 
suggesting that nicotine may improve stimulus filtering (Baschnagl and Hawk 2008). In mice, 
the PPI-enhancing effect of nicotine is strain dependent (Faraday et al. 1999) suggesting 
genetic influences in nicotine-induced modulation of PPI (Kumari and Postma 2005). 
In a recent study by our group, it was demonstrated that variants in CHRNA3, the gene 
encoding for the neuronal acetylcholine receptor subunit α3, are associated with PPI 
(Petrovsky et al. 2010). More precisely, we showed that two common and strongly linked 
CHRNA3 single nucleotide polymorphisms (rs1051730/rs1317286) were associated with PPI 
in two independent samples of healthy human volunteers and patients with schizophrenia 
(Petrovsky et al. 2010). The TT/GG genotype of rs1051730/rs1317286 was associated with 
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decreased PPI levels in both groups (Petrovsky et al. 2010). Our findings from that study 
further support the view that the cholinergic system plays a key role in pre-attentional and 
attentional mechanisms (Bosch and Schmid 2008; Heishman et al. 2010; Hong et al. 2008). 
Moreover, our previous results indicate that there might be shared variance in the molecular 
genetic substrates for both nicotine dependence and sensorimotor gating: interestingly, the 
CHRNA3 rs1051730 T allele and the rs1317286 G allele have been firmly established as risk 
alleles for nicotine dependence (Berrettini et al. 2008; Bierut et al. 2008; Caporaso et al. 2009; 
Saccone et al. 2009). Probably, a genetically induced alteration in the nAChR-system is (in 
part) responsible for both deficits in sensorimotor gating and increased risk for smoking. 
In a recent clinical trial, the α4β2 nAChR agonist varenicline did not improve PPI in a 
sample of smoking and non-smoking patients with schizophrenia or schizoaffective disorder 
(Hong et al. 2011a). However, varenicline reduced startle reactivity regardless of smoking 
status (Hong et al. 2011a). The notion that the α4β2 nAChR agonist varenicline did not 
enhance PPI speaks in favor of the idea that PPI is mainly modulated at the α3 nAChR 
subtype, possibly at the α3β2 or the α3β4 receptors. 
Assuming that individuals with an altered nAChR-system are those individuals who 
exhibit sensorimotor gating deficits and an increased risk for smoking/nicotine dependence, it 
might be the case that these individuals use nicotine in order to self-medicate PPI deficits 
(Kumari and Postma 2005). In particular, there is considerable empirical support for the idea 
that smoking in schizophrenia may represent an attempt to self-medicate some of the 
neurocognitive deficits of this disorder, including PPI (Kumari and Postma 2005). 
Therefore, it would be interesting to test with a pharmacogenetic design whether 
individuals carrying cholinergic variants associated with both diminished PPI and nicotine 
dependence (as it is the case with CHRNA3 rs1051730/rs1317286) display enhanced PPI 
under nicotine application. To date, there is one published study providing evidence that 
dopaminergic polymorphisms might influence the effect of nicotine on PPI in humans 
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(Perkins et al. 2008). However, there are no published pharmacogenetic studies on the 
modulation of nicotine effects by cholinergic polymorphisms regarding PPI, neither in 
animals, nor in humans. 
Thus, based on prior findings on the nicotine-induced enhancement of PPI, the finding 
that the CHRNA3 rs1051730 T-allele has been established as a risk allele for nicotine 
dependence, and based on our previous result that diminished PPI is associated with the 
homozygous CHRNA3 rs1051730 TT genotype, we tested the hypothesis that nicotine 
specifically enhances PPI in CHRNA3 rs1051730 TT carriers. We restricted the present study 
to healthy individuals as this allows the study of pharmacogenetic interactions in the absence 
of clinical and treatment confounds. Finally, we assessed cotinine plasma levels to control for 
individual differences in nicotine uptake from the patches. 
 
Materials and Methods 
Participants 
Healthy volunteers were recruited through local advertisement and by contacting a 
random sample of the inhabitants of Bonn based on a list from the city registry. Non-smoking 
individuals aged between 18 and 55 years were included in the present study. Non-smokers 
were defined as individuals who had smoked no more than 100 cigarettes during their lifetime 
and had not smoked a cigarette in the past year. All participants were screened with the 
Structured Clinical Interview for DSM-IV (SCID-I, German version; Wittchen et al. 1997) to 
exclude participants with a current or lifetime Axis I disorder. Further exclusion criteria 
included head injury with loss of consciousness of >5 min, lifetime history of alcohol or 
substance abuse or dependence, a history of neurological illness or another severe medical 
condition, a relative with psychosis, severe obesity (body mass index BMI >35), and un-
corrected visual impairments and hearing impairments. 
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Furthermore, the following exclusion criteria were employed in order to avoid serious 
side effects caused by the nicotine application: cardiovascular disease, hypertension, atopic or 
eczematous dermatitis (due to localised patch sensitivity), severe renal or hepatic impairment 
or active peptic ulcers, hyperthyroidism, pheochromocytoma, insulin-dependent diabetes, 
hypersensitivity to patches, hypersensitivity to nicotine, or any of the excipients of the 
patches. 
Approval of the local ethics committee and the German Federal Institute for Drugs and 
Medical Devices (BfArM) was obtained and the study was registered with 
http://www.clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT01315002). Participants 
provided written informed consent before inclusion. All subjects were compensated for their 
participation. 
 
Procedures 
A study physician ensured that all inclusion and exclusion criteria were met. On both 
testing days, a urine drug screening test (nal von minden, Moers, Germany) was applied 
before patch application to ensure subjects had abstained from amphetamine, benzodiazepine, 
cocaine, cannabinoides, and opiates. All female subjects additionally underwent a urine 
pregnancy test (Hitado hCG, Hitado Direkt, Endingen, Germany) on both testing days to 
confirm they were not pregnant. 
Nicotine was administered in a double-blind, placebo-controlled, repeated-measures 
design. Each subject completed two startle response testing sessions (one nicotine session and 
one placebo session, the order of sessions was counterbalanced). Nicotine was applied via 
patches (NiQuitin Clear, GlaxoSmithKline, 7mg nicotine patch). Placebo patches (Fink and 
Walter GmbH, Germany) of similar appearance were applied. Both patches were applied non-
visibly to the upper back of the subject by a research assistant who was not running the test 
sessions in order to ensure double-blindness. Acoustic startle measurement commenced three 
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hours after patch application. Nicotine administration using the NiQuitin patch generates a 
fast-rising nicotine plasma level (a nicotine plateau level is achieved after 2 to 4h after 
application according to the Summary of Product Characteristics of NiQuitin Clear). The 
nicotine doses were in accordance with already published studies which demonstrated 
nicotine effects on cognitive functions (Depatie et al. 2002; Levin et al. 1998; Petrovsky et al. 
2012; Poltavski and Petros 2006). Table 1 illustrates the experimental procedures of the two 
testing sessions. 
(Table 1 about here) 
 
Cotinine plasma levels 
Blood samples were collected immediately after the startle measurements in 
anticoagulant EDTA 9ml tubes and centrifuged at 3000rpm for 10min. Plasma was collected, 
allotted to two aliquots, and frozen at -80°C in order to be later analyzed for cotinine. 
Cotinine was quantified with liquid chromatography-mass spectromety (LC-MS), a highly 
specific and sensitive method (Gabr et al. 2011). 
 
Genotyping 
The CHRNA3 rs1051730 single nucleotide polymorphism (SNP) was analyzed by a 
TaqMan assay (Applied Biosystems, Foster City, California). The procedure has been 
described in detail elsewhere (Petrovsky et al. 2010). Genotyping of participants was 
performed after they had completed the two startle response testing sessions. 
 
Startle Response Measurement 
Each examination began with a 2-min acclimation period of 70-dB background noise 
that was continued throughout the session. Participants received 61 white-noise sound pulses 
at an intensity of 115 dB (duration of 40 ms) separated by variable inter-trial intervals (ITIs) 
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between 9 and 17 s (mean=13 s). In 40 of the trials, the pulse was preceded by a 20-ms, 85-dB 
white-noise prepulse with stimulus-onset asynchronies (SOAs) of 30, 60, 120 and 240 ms (10 
trials each). Additionally, participants received 10 no-stimulus-trials in which background 
noise continued and 10 prepulse-alone-trials. Overall, the session consisted of 81 trials. The 
initial trial was a pulse-alone (PA) trial, which was separated for further analysis. All 
following trials were presented in a pseudo-randomized order. The entire test session lasted 
approximately 20 min. Trial exclusion and scoring criteria were identical to those used in 
previous studies (Quednow et al. 2006a; Quednow et al. 2006b). Subjects with response 
rejections >50% were excluded from data analysis. 
 
Statistical analyses 
Startle reactivity was assessed by the mean amplitude of the first block of PA trials 
and the mean amplitude of all PA trials. The mean percent PPI of startle magnitude was 
calculated using the formula [% PPI = 100 × (magnitude on pulse alone (PA) trials - 
magnitude on prepulse (PP) trials)/magnitude on PA trials] (Quednow et al. 2006a; Quednow 
et al. 2006b). For the assessment of startle habituation, PA trials were divided each into four 
blocks. PA trials from the first, second, and third block were taken to calculate PPI (Quednow 
et al. 2006a). The percentage early habituation was calculated as the reduction in startle 
magnitude between the first and second block of PA trials [%HAB=100×(first block–second 
block)/first block]. The percentage total habituation was calculated as the reduction in startle 
magnitude between the first and last block (i.e., the fourth block) of PA trials 
[%HAB=100×(first block–last block)/first block]. Linear gradient coefficient b was calculated 
as a further measure of habituation: [b=(n∑xy–(∑x)(∑y))/(n∑x²–(∑x)²); x=block number, 
y=startle amplitude PA trial per block]. 
All demographic data and psychophysiological parameters were analyzed by analysis 
of variance (ANOVA) with the exception of frequency data. Frequency data were analyzed 
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using χ² tests. Startle reactivity and habituation were analyzed with repeated measures 
analysis of variance (ANOVA) with drug (placebo, nicotine) as within-subjects factor and 
CHRNA3 rs1051730 genotype (TT,TC,CC) and order (placebo/nicotine, nicotine/placebo) as 
between-subjects factors. PPI data were analyzed with repeated measures analysis of 
covariance (ANCOVA) with drug (placebo, nicotine) and SOA (30,60,120,240 ms) as within-
subjects factors and CHRNA3 rs1051730 genotype (TT,TC,CC) and order (placebo/nicotine, 
nicotine/placebo) as between-subjects factors as well as sex as a covariate given that sex is 
known to affect PPI (Swerdlow et al. 1997), and cotinine plasma level as another covariate to 
control for inter-individual differences in the metabolism of nicotine. A paired two-sample t-
test was used to test whether cotinine plasma levels differed between the placebo session and 
the nicotine session (serving as a manipulation check). We also explored whether PPI change 
scores (i.e., difference values: placebo data–nicotine data) were correlated with cotinine 
plasma level using Pearson’s correlations. Greenhouse-Geisser correction of p-values was 
applied when sphericity was violated. P-values of post-hoc tests were Bonferroni-corrected. 
The significance level of all statistical tests was set at p<.05. 
 
Results 
Psychophysiological parameters 
Acoustic startle data from 58 subjects were obtained. Out of these 58 subjects, 3 quit 
the study due to nausea caused by the nicotine application. Out of the remaining 55 subjects, 3 
were identified as startle-non-responders (5.5%) and were excluded from further analyses. 
The proportion of non-responders in our sample is in accordance with observations in other 
samples of healthy volunteers (Blumenthal et al. 2005). Thus, the final sample included 52 
subjects. The rs1051730 genotype groups did not differ regarding age, education, body mass 
index, and sex distribution (see Table 2). Genotype frequencies were distributed in 
accordance with Hardy-Weinberg equilibrium (HWE)(χ²(1)=0.15, p=.69). Genotype groups 
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did not differ regarding early habituation, and total habituation. Confirming our earlier results, 
PPI was considerably lower in TT-allele carriers compared to CC-allele carriers with a 
slightly smaller effect size (d=0.55) as previously reported for healthy subjects (d=0.79) 
(Petrovsky et al. 2010). However, due to the smaller sample and effect size, the overall 
genotype effect was not significant. Also startle reactivity (assessed by the mean amplitude of 
the first block of PA trials) tended to be different between genotype groups with (p=.07, see 
Table 2). Genotype groups differed significantly in habituation slope b (F(2,49)=4.52, p=.02, 
ηp²=.16 )(see Figure 1 and Table 2). Post-hoc testing revealed that TT-carriers did not 
significantly differ from TC-carriers in this habituation coefficient (p=1.00). However, TT-
carriers exhibited a significantly decreased habituation coefficient compared to CC-carriers 
(p=.03). TC-carriers tended to show a decreased habituation coefficient compared to CC-
carriers (p=.055). 
(Table 2 about here) 
(Figure 1 about here) 
 
Effects of nicotine on startle reactivity and habituation 
For startle reactivity and habituation measures there were neither main effects of order 
(all p>.36) nor any interaction of drug×order (all p>.40); thus, this variable was dropped from 
further analyses. Repeated-measures ANOVA of the mean amplitude of PA trials from the 
first block revealed that there was neither a main effect of drug (F(1,49)=1.53, p=.22, ηp²=.03) 
nor an interaction effect of drug×genotype (F(2,49)=0.72, p=.49, ηp²=.03). A similar analysis 
of the mean amplitude of all PA trials showed that there was neither a main effect of drug 
(F(1,49)=2.49, p=.12, ηp²=.05) nor an interaction effect of drug×genotype (F(2,49)=1.03, 
p=.37, ηp²=.04). 
Repeated-measures ANOVA of habituation data (early habituation, total habituation, 
and linear gradient coefficient b) demonstrated that for early habituation, there was neither a 
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main effect of drug (F(1,49)=0.75, p=.39, ηp²=.02) nor an interaction effect of drug×genotype 
(F(2,49)=0.29, p=.75, ηp²=.01). However, there was a significant main effect of drug 
(F(1,49)=5.59, p=.02, ηp²=.10) on total habituation indicating less habituation under nicotine 
as compared to placebo (see Table 3). No significant interaction of drug×genotype on total 
habituation was found (F(2,49)=1.32, p=.28, ηp²=.05). Regarding linear gradient coefficient b, 
neither a significant main effect of drug (F(1,49)=2.78, p=.10, ηp²=.05), nor a significant 
interaction of drug×genotype was found (F(2,49)=0.24, p=.79, ηp²=.01). 
(Table 3 about here) 
 
Effects of nicotine on prepulse inhibition 
Repeated-measures ANCOVA of PPI data revealed that there was neither a main 
effect nor any interaction effects of order (all p>.44); thus this variable was dropped from 
further analyses. There was no main effect of drug (F(1,46)=0.20, p=.66, ηp²=.004), however, 
there was a significant interaction of drug×genotype (F(2,46)=3.83, p=.03, ηp²=.14) indicating 
that the effect of nicotine on mean PPI across SOAs was modulated by CHRNA3 rs1051730 
genotype. Post-hoc testing revealed that TT-genotype-carriers of CHRNA3 rs1051730 
exhibited increased PPI under nicotine as compared to placebo (p=.03) whereas there was a 
trend for nicotine decreasing PPI in TC-carriers as compared to placebo (p=.16). The effect of 
nicotine in CC-carriers was similar to the one in TC-carriers: nicotine tended to decrease PPI 
as compared to placebo, although this effect was not statistically significant (p=.28) (see 
Figure 2).  
 
(Figure 2 about here) 
 
There was also significant triple interaction of drug×genotype×SOA (F(6,138)=2.43, 
p=.04, ηp²=.10) indicating the interaction of drug×genotype was modulated by SOA. Post-hoc 
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testing revealed that in TT-carriers and TC-carriers the drug-by-genotype interaction was 
significant for the SOAs 120ms and 240ms, but not for the SOAs 30ms and 60ms (see Figure 
3). In CC-carriers pattern of results was similar, but not statistically significant. We also 
found a main effect of SOA (F(3,138)=3.78, p=.03, ηp²=.20), replicating the well-known 
nature of PPI to increase with rising SOA from 30ms to 120ms and to decrease from SOA 
240ms onwards (Blumenthal 1999). No significant interaction of SOA×genotype 
(F(1,46)=1.38, p=.25, ηp²=.05), and no significant interaction of SOA×drug (F(1,46)=0.15, 
p=.90, ηp²=.003) was found. As startle reactivity (assessed by the mean amplitude of the first 
block of PA trials) tended to be different between genotype groups (p=.07, see Table 2) we 
added startle reactivity as an additional covariate to the statistical design (Csomor et al. 2008). 
Adding startle reactivity as an additional covariate to the statistical design did not change 
results regarding the lack of main effects of drug or genotype. Likewise, all interaction effects 
were not substantially altered by startle reactivity. The interaction of drug×genotype remained 
significant (F(2,45)=3.93, p=.03, ηp²=.14) and the triple interaction of drug×genotype×SOA 
also survived (F(6,135)=2.42, p=.04, ηp²=.10). 
 
(Figure 3 about here) 
 
Cotinine plasma levels 
Cotinine data of 51 participants were available. Mean cotinine plasma levels were 
significantly higher for the nicotine session (mean cotinine=16.48±2.68 ng/ml) than for the 
placebo session (t(50)=9.48, p<.1×10-30) indicating a successful experimental manipulation. 
In total, PPI change scores were not significantly correlated with cotinine plasma level but in 
TC-carriers, PPI change scores tended to correlate with cotinine levels (r=.36, p=.09) 
indicating that with nicotine-induced decrease of PPI were associated with increased cotinine 
plasma level. 
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Discussion 
The present study demonstrated that the effect of nicotine on PPI is modulated by a 
single nucleotide polymorphism in the cholinergic receptor gene CHRNA3. Nicotine 
significantly enhanced PPI in rs1051730 TT-homozygotes only, who displayed the lowest PPI 
levels, and tended to worsen PPI in TC- and CC-carriers, who showed normal PPI levels. In 
contrast, nicotine did not influence startle reactivity but significantly reduced total habituation 
of pulse-alone trials independent of genotype. 
To our knowledge, this is the first pharmacogenetic study investigating the impact of a 
cholinergic receptor gene on the effect of nicotine on PPI. Our finding suggest that 
experiencing neurocognitive enhancement from nicotine application might represent another 
contributing factor in the development and maintenance of nicotine addiction – in line with 
the previously reported self-medication hypothesis (Kumari and Postma 2005). It remains 
unclear, however, which mechanisms are responsible for the beneficial effect of nicotine on 
PPI exclusively in TT-carriers. Possibly, an individual being TT-homozygous for the SNP 
rs1051730 is more susceptible for positive effects of nicotine (i.e., neurocognitive 
enhancement, elevated mood, etc.) and thereby more prone to develop and maintain nicotine 
dependence. Another, not mutually exclusive, possibility is that individuals with one or more 
copies of the T-allele may be more resistant to the aversive side effects of nicotine (Munafo et 
al. 2011). Interestingly, it is the T-allele of the rs1051730 polymorphism which has been 
repeatedly associated with nicotine dependence (Berrettini et al. 2008; Bierut et al. 2008; 
Caporaso et al. 2009; Saccone et al. 2009). Moreover, there is evidence for an association 
between the T-allele of the rs1051730 polymorphism and decreased likelihood of smoking 
cessation (Munafo et al. 2011) – further emphasizing the role of the T-allele in the context of 
nicotine dependence and smoking behavior. 
PPI is classified as an established endophenotype or biomarker of schizophrenia (Braff 
et al. 2001). Therefore, it would also be interesting to investigate whether the present 
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pharmacogenetic interaction of a cholinergic SNP and nicotine on PPI can be found in 
schizophrenia patients. The T-allele of the rs1051730 polymorphism is not known to be a risk 
allele for schizophrenia, however, in our previous study we demonstrated an association with 
chronicity, treatment, and negative symptoms in our schizophrenia sample (Petrovsky et al. 
2010). To date, there is no published study investigating the pharmacogenetic interaction of a 
cholinergic polymorphism with nicotine on neurocognition in schizophrenia. So far, there is 
only one published study providing direct molecular genetic evidence for the smoking-
schizophrenia comorbidity (Hong et al. 2011b). That study revealed that the CHRNA5 SNP 
rs16969968 (Asp398Asn) was simultaneously linked to smoking and schizophrenia in the 
same cohort (Hong et al. 2011b). Thus, it remains to be investigated whether genetic variants 
within the CHRNA3/CHRNA5 gene cluster modulate the effects of nicotine on schizophrenia 
endophenotypes in patient samples. 
An important point is that in the present investigation, we tested the effect of acute 
nicotine in non-smokers (individuals relatively naïve to nicotine): it is possible that in 
smokers, the modulating gene effect on the response to nicotine might be different. In a recent 
study, schizophrenia risk polymorphisms in the TCF4 gene interacted with smoking in the 
modulation of P50 sensory gating (Quednow et al. 2012). In that study, only smokers reliably 
showed TCF4-P50 suppression associations, whereas the genetic effect was small or not 
present in never-smokers. Moreover, genotype-smoking interactions were dose-related, 
because TCF4 SNP genotype effects amplified with increasing smoking severity. The results 
from that study might represent an example of a gene-environment interaction, in which 
smoking represents a long-lasting and ongoing environmental influence (Quednow et al. 
2012). Thus, it would be of interest to investigate pharmacogenetic effects on gating 
mechanisms in smokers to further disentangle the causal relationships between diminished 
gating performance, nicotine sensitivity, nicotine intake, and genetic variation. 
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Limitations of the present study include the relatively small sample size of the 
genotype groups. A related issue involves the non-significant main effect of genotype on PPI 
(i.e. significantly diminished PPI in TT-carriers) as in our previous study (Petrovsky et al. 
2010). However, numerically the TT-genotype group did show the smallest PPI with 
considerable effect size. Presumably, our sample was not large enough in order to 
significantly replicate our previous association as the present study's sample was much 
smaller than the prior one. Therefore, the present results should be regarded as preliminary 
requiring replication in a larger sample. 
In conclusion, we demonstrated that the effect of nicotine on sensorimotor gating is 
modulated by a CHRNA3 polymorphism confirming a major role of α3-subunits of the 
nAChR in the mediation of PPI. We showed that carriers of a risk allele for nicotine 
dependence are also those individuals whose PPI is enhanced by nicotine. Thus, genetic 
variation in cholinergic genes might be an important connecting link between cognitive 
deficits and smoking behavior. Finally, α3-subunits might represent new targets for 
developing pharmacological treatment of cognitive dysfunction in schizophrenia and in other 
disorders. 
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Tables 
Table 1 Experimental procedure of the two testing sessions. 
 
Before patch application: 
 
Visit study physician and informed consent (at session 1) (t-60 min) 
Urine drug screening test (additionally in females: urine pregnancy test)(t-45 min) 
Patch application  Administration of 7mg nicotine or placebo (t0) 
3-hour-waiting time: SCID-I interview (t+5 min) 
Verbal IQ testing (t+60 min) 
Collect demographic data (t+70 min) 
Participants were allowed to read and drink water (t+90-160 min) 
Application of the electrodes (t+160 min) 
3 hours after patch 
application: 
 
Acoustic startle measurement (t+180 min) 
Taking of blood sample for cotinine plasma levels and genotyping (t+200 min) 
Patch removal (t+215 min) 
Debriefing and financial compensation (at session 2) 
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Table 2 Demographic characteristics and psychophysiological parameters of participants. 
CHRNA3 rs1051730 genotype TT TC CC Total F/χ² df/dferr p ηp² 
N 10 (19.2%) 24 (46.2%) 18 (34.6%) 52 (100%)     
Age (years) 32.00 (13.08) 27.75 (6.33) 27.83 (8.20) 28.60 (8.57) 0.98 2/49 .38 .04 
Years of education 16.20 (2.25) 16.33 (0.87) 16.44 (1.98) 16.35 (1.60) 0.74 2/49 .93 .003 
Body mass index (BMI) 23.81 (4.55) 23.30 (3.52) 24.33 (3.64) 23.76 (3.72) 0.38 2/49 .69 .02 
Men (%) 40.0 54.2 77.8 59.6 4.36 2 .11 - 
Placebo condition: First block, 
amplitude of pulse-alone trials 
(arbitrary units) 
241.82 (175.78) 290.89 (239.63) 447.52 (293.12) 335.67 (258.99) 2.89 2/49 .07 .11 
Placebo condition: Mean amplitude 
of pulse-alone trials (arbitrary units) 185.63 (148.44) 215.89 (212.73) 317.71 (259.81) 245.32 (223.06) 1.55 2/49 .22 .06 
Placebo condition: Mean percent 
prepulse inhibition (overall PPI, 
averaged over all SOAs) 
33.50 (25.85) 37.58 (28.08) 47.66 (22.66) 40.29 (26.01) 1.20 2/49 .31 .05 
Placebo condition: Percent early 
habituation of pulse-alone trials 
(between first and second block) 
25.38 (31.41) 29.47 (22.67) 34.85 (22.29) 30.55 (24.16) 0.53 2/49 .59 .02 
Placebo condition: Percent total 
habituation of pulse-alone trials 
(between first and fourth block) 
37.31 (26.10) 47.38 (24.90) 52.71 (24.16) 47.29 (24.99) 1.23 2/49 .30 .05 
Placebo condition: Habituation of 
pulse-alone trials across 4 blocks 
(linear gradient coefficient b) 
-29.24 (26.32) -39.78 (31.46) -67.46 (45.82) -47.33 (38.76) 4.52 2/49 .02a .16 
Legend. Data represent means (standard deviations) unless otherwise specified. 
aBonferroni post-hoc tests: TT > TC p=1.00, TT > CC p=.03, TC > CC p=.055 
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Table 3 The effect of nicotine on startle reactivity, prepulse inhibition and habituation. 
CHRNA3 rs1051730 
genotype TT 
 TC  CC  Total  
 Placebo Nicotine  Placebo Nicotine  Placebo Nicotine  Placebo Nicotine  
Significant 
main 
effect of 
drug? 
Significant 
interaction of 
drug×genotype? 
First block, amplitude of 
pulse-alone trials (arbitrary 
units) 
241.82 
(175.78) 
239.39 
(223.48) 
 290.89 
(239.63) 
276.75 
(216.89) 
 447.52 
(293.12) 
391.33 
(320.69) 
 335.67 
(258.99) 
309.22 
(261.04) 
 No No 
Mean amplitude of pulse-
alone trials (arbitrary units) 
185.63 
(148.44) 
180.12 
(187.60) 
 215.89 
(212.73) 
205.43 
(186.37) 
 317.71 
(259.81) 
272.47 
(247.87) 
 245.32 
(223.06) 
223.77 
(209.10) 
 No No 
Mean percent prepulse 
inhibition (overall PPI, 
averaged over all SOAs) 
33.50 
(25.85) 
43.58 
(16.95) 
 37.58 
(28.08) 
33.75 
(28.99) 
 47.66 
(22.66) 
43.63 
(25.91) 
 40.29 
(26.01) 
39.06 
(26.04) 
 No Yesa 
Percent early habituation of 
pulse-alone trials (between 
first and second block) 
25.38 
(31.41) 
28.23 
(26.74) 
 29.47 
(22.67) 
30.18 
(28.97) 
 34.85 
(22.29) 
42.37 
(19.74) 
 30.55 
(24.16) 
34.02 
(25.94) 
 No No 
Percent total habituation of 
pulse-alone trials (between 
first and fourth block) 
37.31 
(26.10) 
17.95 
(55.15) 
 47.38 
(24.90) 
36.30 
(30.63) 
 52.71 
(24.16) 
51.80 
(27.45) 
 47.29 
(24.99) 
38.14 
(36.86) 
 Yesb No 
Habituation of pulse-alone 
trials across 4 blocks (linear 
gradient coefficient b) 
-29.24 
(26.32) 
-24.68 
(29.12) 
 -39.78 
(31.46) 
-31.17 
(29.47) 
 -67.46 
(45.82) 
-53.39 
(41.85) 
 -47.33 
(38.76) 
-37.61 
(35.57) 
 No No 
Legend. Data represent means (standard deviations). Nicotine=nic, placebo=plac. 
aInteraction of drug×genotype (F(2,46)=3.83, p=.03, ηp²=.14). Bonferroni post-hoc tests: TT: nic>plac p=.03, TC: nic<plac p=.16, CC: n<plac p=.28. 
bMain effect of drug (F(1,49)=5.59, p=.02, ηp²=.10) indicating less habituation under nicotine as compared to placebo. 
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Figure legends 
 
Figure 1 Placebo condition: habituation curves diagrammed as mean amplitude of pulse-alone (PA) trials in 4 blocks across CHRNA3 rs1051730 
genotype groups (means±SEM). 
 
Legend. Genotype groups differed significantly in habituation of pulse-alone trials across all four blocks (linear coefficient b )(p=.02). Post-hoc 
testing revealed that there was no difference between TT-carriers and TC-carriers (p=1.00). TT-carriers exhibited a decreased habituation coefficient 
compared to CC-carriers (p=.03). TC-carriers tended to show a decreased habituation coefficient compared to CC-carriers (p=.055). 
 
Figure 2 The effect of nicotine on mean PPI across SOAs is modulated by CHRNA3 rs1051730 genotype in 52 healthy non-smoking human 
volunteers (means±SEM, adjusted for sex). 
 
Legend. There was a significant interaction of drug × genotype (p=.03). Post-hoc testing revealed that nicotine enhanced PPI in CHRNA3 rs1051730 
TT-carriers (p=.03) while nicotine non-significantly tended to worsen PPI in TC-carriers (p=.06) and CC-carriers (p=.13). 
 
Figure 3 The effects of nicotine on mean PPI for each SOA and CHRNA3 rs1051730 genotype (means±SEM, adjusted for sex). 
 
Legend. There was a significant triple interaction of drug × genotype × SOA (p=.04) indicating the interaction of drug × genotype was modulated 
by SOA. Post-hoc testing showed that the interaction effect was more pronounced for SOAs 120 ms and 240 ms than for SOAs 30 ms and 60 ms. 
 



